NO301419B1 - 2-okso-5-oksazolidinmetylforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse derav for fremstilling av legemidler - Google Patents

2-okso-5-oksazolidinmetylforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse derav for fremstilling av legemidler

Info

Publication number
NO301419B1
NO301419B1 NO941592A NO941592A NO301419B1 NO 301419 B1 NO301419 B1 NO 301419B1 NO 941592 A NO941592 A NO 941592A NO 941592 A NO941592 A NO 941592A NO 301419 B1 NO301419 B1 NO 301419B1
Authority
NO
Norway
Prior art keywords
pharmaceuticals
oxo
manufacture
pharmaceutical compositions
compositions containing
Prior art date
Application number
NO941592A
Other languages
English (en)
Other versions
NO941592D0 (no
NO941592L (no
Inventor
Peter Raddatz
Joachim Gante
Horst Juraszyk
Hanns Wurziger
Helmut Pruecher
Sabine Bernotat-Danielowski
Guido Melzer
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4405633A external-priority patent/DE4405633A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO941592D0 publication Critical patent/NO941592D0/no
Publication of NO941592L publication Critical patent/NO941592L/no
Publication of NO301419B1 publication Critical patent/NO301419B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
NO941592A 1993-05-01 1994-04-29 2-okso-5-oksazolidinmetylforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse derav for fremstilling av legemidler NO301419B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4314378 1993-05-01
DE4405633A DE4405633A1 (de) 1993-05-01 1994-02-22 Adhäsionsrezeptor-Antagonisten

Publications (3)

Publication Number Publication Date
NO941592D0 NO941592D0 (no) 1994-04-29
NO941592L NO941592L (no) 1994-11-02
NO301419B1 true NO301419B1 (no) 1997-10-27

Family

ID=25925455

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941592A NO301419B1 (no) 1993-05-01 1994-04-29 2-okso-5-oksazolidinmetylforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse derav for fremstilling av legemidler

Country Status (16)

Country Link
US (1) US5532255A (no)
EP (1) EP0623615B1 (no)
JP (1) JP3570744B2 (no)
CN (1) CN1052231C (no)
AT (1) ATE181735T1 (no)
AU (1) AU675698B2 (no)
CA (1) CA2122571C (no)
CZ (1) CZ285761B6 (no)
DK (1) DK0623615T3 (no)
ES (1) ES2134870T3 (no)
GR (1) GR3031271T3 (no)
HU (1) HU224549B1 (no)
NO (1) NO301419B1 (no)
PL (1) PL178131B1 (no)
RU (1) RU2145961C1 (no)
SK (1) SK281469B6 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
DE4429461A1 (de) * 1994-08-19 1996-02-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19504954A1 (de) * 1995-02-15 1996-08-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
KR20000005117A (ko) * 1996-03-30 2000-01-25 로셰 디아그노스틱스 게엠베하 신규한 옥사졸리딘 유도체, 이들의 제조 방법 및 이들을 함유하는 약제
US5925635A (en) * 1996-04-17 1999-07-20 Dupont Pharmaceuticals Company N-(amidinophenyl) cyclourea analogs as factor XA inhibitors
US5877166A (en) * 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
DE19755268A1 (de) * 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
WO1999064417A2 (en) 1998-06-05 1999-12-16 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
AU5336299A (en) * 1998-08-07 2000-02-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19835950A1 (de) * 1998-08-08 2000-02-10 Merck Patent Gmbh Piperazinonderivate
US6303609B1 (en) 1998-11-18 2001-10-16 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
CA2356748A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
DE19958153A1 (de) * 1999-12-03 2001-06-07 Yamanouchi Pharma Co Ltd Oxazolidinon-Derivate
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10152460A1 (de) * 2001-10-24 2003-05-08 Bayer Ag Stents
WO2003061715A1 (en) 2002-01-22 2003-07-31 Pharmacia & Upjohn Company Infection-resistant medical devices
US7141588B2 (en) * 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
JP4664634B2 (ja) * 2003-09-05 2011-04-06 富山化学工業株式会社 新規なベンズアミジン誘導体またはその塩
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
MX2007002772A (es) 2004-09-07 2008-03-05 Archemix Corp Aptameros para el factor de von willebrand y su uso como agentes terapeuticos para la enfermedad trombotica.
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
CA2624310C (en) 2005-10-04 2014-01-07 Bayer Healthcare Ag Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) * 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
DE102007018662A1 (de) * 2007-04-20 2008-10-23 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
DE102007028318A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
CN101896185A (zh) * 2007-12-11 2010-11-24 拜耳先灵制药股份公司 治疗和/或预防心力衰竭的噁唑烷酮
EP2138178A1 (en) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
EP2140866A1 (en) 2008-07-04 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
AU2016288230A1 (en) 2015-07-02 2018-01-25 Horizon Orphan Llc ADO-resistant cysteamine analogs and uses thereof
MX2019010267A (es) 2017-02-28 2020-02-05 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
US20200071322A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting (alpha-v)(beta-6) integrin
WO2023172726A1 (en) * 2022-03-10 2023-09-14 Baruch S. Blumberg Institute Novel diazepines that target yellow fever virus non-structural 4b (ns4b) protein and their method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1222708A (en) * 1968-10-22 1971-02-17 Delalande Sa Novel 5-(n-substituted aminomethyl)-2-oxazolidinones and their process of preparation
US4886794A (en) * 1987-05-07 1989-12-12 A. H. Robins Company, Incorporated 4-[(α,α-diaryl)-hydroxymethyl]-1-piperidinylalkyl-cyclic carbamate derivatives as allergic response inhibitors
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4005371A1 (de) * 1990-02-21 1991-08-22 Merck Patent Gmbh Oxazolidinone
DE4017211A1 (de) * 1990-05-29 1991-12-05 Merck Patent Gmbh Oxazolidinone
US5086055A (en) * 1990-12-24 1992-02-04 A. H. Robins Company, Incorporated Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions
DE4324393A1 (de) * 1993-07-21 1995-01-26 Merck Patent Gmbh 4-Aryloxy- und 4-Arylthiopiperidinderivate

Also Published As

Publication number Publication date
US5532255A (en) 1996-07-02
JPH072847A (ja) 1995-01-06
JP3570744B2 (ja) 2004-09-29
RU2145961C1 (ru) 2000-02-27
CA2122571C (en) 2005-04-12
CZ285761B6 (cs) 1999-11-17
HU224549B1 (hu) 2005-10-28
SK281469B6 (sk) 2001-04-09
GR3031271T3 (en) 1999-12-31
ES2134870T3 (es) 1999-10-16
AU675698B2 (en) 1997-02-13
CN1097421A (zh) 1995-01-18
EP0623615A1 (de) 1994-11-09
NO941592D0 (no) 1994-04-29
EP0623615B1 (de) 1999-06-30
DK0623615T3 (da) 1999-12-13
CN1052231C (zh) 2000-05-10
AU6064394A (en) 1994-11-03
HUT70541A (en) 1995-10-30
CA2122571A1 (en) 1994-11-02
SK48494A3 (en) 1995-02-08
HU9401274D0 (en) 1994-08-29
ATE181735T1 (de) 1999-07-15
CZ101994A3 (en) 1994-11-16
NO941592L (no) 1994-11-02
PL178131B1 (pl) 2000-03-31

Similar Documents

Publication Publication Date Title
NO301419B1 (no) 2-okso-5-oksazolidinmetylforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse derav for fremstilling av legemidler
IL93170A0 (en) Carboxylic and sulphonic acid amides,their preparation and pharmaceutical compositions containing them
NO305203B1 (no) Oksazolidinonderivater, farmas°ytiske preparater som inneholder minst Ún slik forbindelse, og anvendelse av forbindelsene for fremstilling av legemidler
SE8700499D0 (sv) Novel pharmacologically active compounds
FI922481A0 (fi) Heterocykliska derivat.
GR3018182T3 (en) Derivatives of amidinophenylalanine, procedure for their preparation, their utilisation and anticoagulant compositions comprising them.
DK0580502T3 (da) 3-(hydroxybenzylidenyl)-indolin-2-oner og farmaceutiske sammensætninger indeholdende disse
FI890311A (fi) Kemiska foereningar.
IL82084A0 (en) 1,4-diazepines,their preparation and pharmaceutical compositions containing them
DE68906609D1 (de) Dopamin-vorlaeufer.
KR960703863A (ko) 암 치료용 신규 비스-나프탈이미드(New Bis-naphthalimides for the Treatment of Cancer)
SE8600658D0 (sv) Novel composition of matter
NO884523L (no) Joderte polymerer, fremgangsmaate for deres fremstilling og deres anvendelse som kontrastmidler.
KR960004860B1 (en) Substituted pyridine-2,4-dicarboxylic acid compounds and the use thereof and medicaments
GR3002558T3 (en) Synergistinic derivatives, their preparation and pharmaceutical compositions containing them
DK284588A (da) Beta-lactam-forbindelser, deres fremstilling og anvendelse som laegemidler.
DK0418990T3 (da) 13-brom- og 13,14-dibrom-ergoliner, deres fremstilling og anvendelse i lægemidler
FI903701A0 (fi) Reninhaemmande amino-oligohydroxiderivat.
IL103855A0 (en) 5,6-dihydro-dibenz(b,e)azepin-6,11-dione-11-oximes,their preparation and pharmaceutical compositions containing them
IL67400A0 (en) 3,7alpha-diazacyclohepta(j,k)fluorene derivatives,their preparation and pharmaceutical compositions containing them
EE9400233A (et) 1,5,6,7-tetrahüdro-4H-indasool-4-ooni sisaldav ravim, uus 1,5,6,7-tetrahüdro-4H-indasool-4-oon ja meetodid nende saamiseks

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN OCTOBER 2003